Trial Profile
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Feb 2016
Price :
$35
*
At a glance
- Drugs Mitoxantrone (Primary) ; Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 25 Feb 2016 New trial record